CJC-1295 Peptide Therapy; Growth and Wellness Hormone

CJC-1295 is a synthetic peptide that functions as a modified version of growth hormone-releasing hormone (GHRH). Designed to enhance growth hormone production, this peptide represents a significant advancement in peptide therapy, featuring a unique 29-amino acid structure that optimizes its stability and effectiveness in the body

CJC-1295 & Its Characteristics

Modified GHRH analog

Numerous modifications have been made to growth hormone-releasing hormone (GHRH) to create analogs that retain some of the hormone's properties while removing others. Only the first 29 amino acids of GHRH make up one of such changes, CJC-1295. This GHRH analog, which is actually a maleimide derivative of hGRF(1-29), was developed to create a more soluble GH secretagogue that maintains the physiological effects of GHRH while being simpler to make in large numbers. 

Development background

As a modified form of the first 29 amino acids of GHRH in metabolism, CJC-1295 shares chemical similarities with other GHRH analogs, such as Sermorelin; it is most similar to modified GRF (1-29), although the two peptides are not the same. The similarities between these peptides and the fact that CJC-1295 was initially made with an additional chemical compound known as the drug affinity complex (DAC) cause a lot of confusion [1].

Half-life characteristics

Studies have shown that CJC-1295 without DAC has a longer half-life of roughly 30 minutes because of its shortened 29-amino acid structure, which has four amino acids added to improve stability.

Peptide structural changes take place at particular locations with the goal of enhancing resistance to dipeptidyl peptidase-4 enzymatic degradation. These changes are:

• Position 2: To possibly improve resistance to enzymatic degradation, L-alanine can be substituted with D-alanine.

• Position 8: To lessen the possibility of asparagine rearrangement and amide hydrolysis, glutamine is substituted for asparagine.

• Position 15: Glycine is replaced with alanine, which is thought to increase bioactivity.

• Position 27: Leucine is substituted for methionine in order to perhaps stop methionine oxidation.

By decreasing enzymatic degradation and enhancing stability under physiological settings, these modifications in growth hormone levels seek to improve the peptide's robustness and functional effectiveness. Additionally, it's thought that using DAC technology will increase the peptide's half-life to roughly 6–8 days.

Basic properties

It functions by raising the concentration of growth-related hormones in the blood. It can speed up the healing process from injuries, reduce body fat, build strength and muscle mass, and even enhance cognitive function and sleep quality.

Mechanism of Action

The metabolic complex known as the DAC component is believed to further extend the peptide's half-life. The DAC's capacity to attach to plasma proteins is responsible for this improvement. N-epsilon-3-maleimidopropionamide, a lysine derivative, is specifically attached to the C-terminus of CJC-1295 DAC as part of the DAC component. By combining this altered amino acid sequence with the DAC component, CJC-1295 DAC's pharmacokinetics may be supported, possibly increasing its half-life to about eight days. At the same time, it retains an elevated preference for GHRH receptors, comparable to that of CJC-1295 in the absence of DAC.

In modern studies, CJC-1295 without DAC is also relevant. For example, the synergistic potential of CJC-1295  and Ipamorelin has been investigated. It is hypothesized that this combination of GHRH analogs and peptides that appear to activate pituitary ghrelin receptors will cause somatotroph cells to produce a greater amount of GH. [3]

Research Evidence of CJC-1295 Peptide

 In 2006, researchers looked into the impact of CJC-1295 DAC through two important clinical studies. One of four increasing concentrations of CJC-1295 DAC or a control chemical was used in the first research. In the second study, CJC-1295 DAC was exposed repeatedly at a single concentration.

The results showed that exposure to CJC-1295 DAC appeared to raise levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-I). It is thought that CJC-1295 DAC raises IGF-1 levels by inducing the generation of growth hormone, which may attach to liver cell receptors and initiate intracellular signaling pathways.

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway may be triggered by this interaction, which would result in the transcription of the IGF-I gene. Following production, the IGF-I may be sent to different target tissues, where it may have an anabolic effect and stimulate growth.

Investigation has demonstrated that CJC-1295 maintains normal GH release in animals lacking normal GHRH physiology [2]. Because of this, the peptide may be found to be an application in treating aberrant growth in humans and other mammalian species. Maintaining GH's regular pulsatile release is essential for the appropriate release of downstream hormones, including insulin-like growth factor-2 (IGF-1).

CJC-1295 and other growth hormone-releasing factor (GRF) analogs may help infertile female organisms ovulate, according to research from the early 1990s. These models reportedly displayed "a significant increase of both follicular fluid IGF-I levels (compared to the previous cycle) and plasma GH levels immediately." [4] Insulin-like growth factor-1 (IGF-1) is thought to be necessary for ovulation, and growth hormone (GH) production and cycling probably have an impact as well.

Research conducted on animal models of superovulation has shown that around the time of ovulation, both GH and IGF-1 levels may rise noticeably. These results suggest that adequate ovulation may be induced by external exposure to GH secretagogues, such as CJC-1295.

Research Applications for CJC-1295 Peptide

Opportunities of CJC-1295 DAC were explored more thoroughly in murine models through further animal investigations. According to the findings of one investigation, regular administration of CJC-1295 DAC peptide has the potential to entirely normalize growth.

It appeared that the peptide was administered every two or three days, which indicated that it created an intermediate influence, indicating that its action was interval-dependent. According to the findings of the study, CJC-1295 DAC may have an effect on mass composition by achieving an increase in muscle tissue hypertrophy while simultaneously achieving a potential reduction in fat tissue levels.

CJC-1295 DAC treatment appeared to sustain normal lean mass levels and maintain subcutaneous fat mass consistent with control levels in GHRHKO mouse models. This is in contrast to mice that did not get exposure, which reportedly exhibited elevated fat levels.

In addition, the researchers indicate that "CJC-1295 caused a spike in total pituitary RNA and GH mRNA, implying that multiplication of somatotroph cells had occurred." This wellness assertion is based on the immunohistochemical images that were obtained [5]. 

Future Research Perspectives 

The synthetically produced peptide known as CJC-1295 was initially developed for the purpose of treating ailments. However, it was later revealed that it also possesses performance-enhancing benefits that are beneficial to athletes, bodybuilders, and anybody else involved in fitness. 

According to the findings of one research investigation, CJC-1295 has the capacity to raise serum growth hormone levels by between 200-1000% when it is supplied through the use of an injection that is self-administered. As a result of this remarkable procedure, CJC-1295 has been utilized to enhance the health and well-being of elderly individuals as well as people who are looking to get greater results in their workout routines. 

CJC-1295 has been shown to have a number of potential advantages, which are may include:

• A more restful night's sleep

• Increase in muscle mass

• Ability to strengthen the immune system and improve the time it takes to recover from injuries and repair damage

• Improvements in cognitive performance and mental discernment

• Enhancing the flexibility of the skin, lessens the appearance of wrinkles, and fortifies the nails and hair

• An increase in both calories and metabolic rate leads to an increase in fat loss. 

References

1. Van Hout, M. C., & Hearne, E. (2016). Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions. Substance Use & Misuse, 51(1), 73-84.

2. Henninge, J., Pepaj, M., Hullstein, I., & Hemmersbach, P. (2010). Identification of CJC‐1295, a growth‐hormone‐releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2(11‐12), 647-650.

3. Sackmann-Sala, Lucila, Juan Ding, Lawrence A. Frohman, and John J. Kopchick. "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects." Growth Hormone & IGF Research 19, no. 6 (2009): 471-477.

4. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.

5. Should ask Gavin, Y. Dat's-CJC-1295 & GHRP-6 (Basic Guides).